MA54943A - Production de compositions comprenant deux anticorps ou plus - Google Patents

Production de compositions comprenant deux anticorps ou plus

Info

Publication number
MA54943A
MA54943A MA054943A MA54943A MA54943A MA 54943 A MA54943 A MA 54943A MA 054943 A MA054943 A MA 054943A MA 54943 A MA54943 A MA 54943A MA 54943 A MA54943 A MA 54943A
Authority
MA
Morocco
Prior art keywords
antibodies
compositions
production
Prior art date
Application number
MA054943A
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Robert Paul Doornbos
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA54943A publication Critical patent/MA54943A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
MA054943A 2019-02-14 2020-02-13 Production de compositions comprenant deux anticorps ou plus MA54943A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157286 2019-02-14
EP19178542 2019-06-05

Publications (1)

Publication Number Publication Date
MA54943A true MA54943A (fr) 2021-12-22

Family

ID=69771002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054943A MA54943A (fr) 2019-02-14 2020-02-13 Production de compositions comprenant deux anticorps ou plus

Country Status (13)

Country Link
US (1) US20220127375A1 (fr)
EP (1) EP3924377A1 (fr)
JP (2) JP7375027B2 (fr)
KR (1) KR20210126699A (fr)
AU (1) AU2020221649A1 (fr)
BR (1) BR112021016092A2 (fr)
CA (1) CA3130246A1 (fr)
IL (1) IL285489A (fr)
MA (1) MA54943A (fr)
MX (1) MX2021009769A (fr)
SG (1) SG11202108840XA (fr)
TW (1) TW202045132A (fr)
WO (1) WO2020167122A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920275A (zh) * 2017-07-06 2019-06-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
US20220281914A1 (en) * 2020-12-18 2022-09-08 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856324A (zh) * 2002-09-17 2006-11-01 Gtc生物治疗学公司 缺乏重链间二硫键的免疫球蛋白分子的分离
CA2527694C (fr) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Banque de fab pour la preparation de fab anti-vegf et antirabique
EP2471816A1 (fr) 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
EP2147594B1 (fr) 2008-06-27 2013-11-13 Merus B.V. Mammifères non humains produisant un anticorps
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
RU2606264C2 (ru) * 2009-12-25 2017-01-10 Чугаи Сеияку Кабушики Каиша Способ полипептидной модификации для очистки полипептидных мультимеров
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
EP3036253B1 (fr) * 2013-08-19 2020-09-23 F. Hoffmann-La Roche AG Séparation des anticorps bispécifiques et des produits accessoires de production d'anticorps bispécifiques utilisant une chromatographie hydroxyapatite
AU2018279278A1 (en) * 2017-06-05 2019-12-19 Janssen Biotech, Inc. Methods of engineering surface charge for bispecific antibody production

Also Published As

Publication number Publication date
TW202045132A (zh) 2020-12-16
EP3924377A1 (fr) 2021-12-22
US20220127375A1 (en) 2022-04-28
JP7375027B2 (ja) 2023-11-07
SG11202108840XA (en) 2021-09-29
IL285489A (en) 2021-09-30
CA3130246A1 (fr) 2020-08-20
AU2020221649A1 (en) 2021-09-02
BR112021016092A2 (pt) 2021-10-26
JP2023171492A (ja) 2023-12-01
JP2022520972A (ja) 2022-04-04
MX2021009769A (es) 2021-09-08
WO2020167122A1 (fr) 2020-08-20
KR20210126699A (ko) 2021-10-20

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA51734A (fr) Anticorps se liant à gprc5d
MA53434A (fr) Anticorps anti-tigit
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
MA52884A (fr) Anticorps anti-il-11
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA49034A (fr) Anticorps anti-lag3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
MA47268A (fr) Anticorps anti-gpc3
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
MA50352A (fr) Anticorps multispécifiques
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
MA52366A (fr) Anticorps anti-tl1a optimisés
MA45450B1 (fr) Formulations d'anticorps anti-cd19
MA54139A (fr) Formulation d'anticorps
MA54052A (fr) Formulation d'anticorps
MA52152A (fr) Anticorps
MA51134A (fr) Anticorps anti-alpha-synucléine
MA51212A (fr) Anticorps neutralisant les polyomavirus
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha